Category Archives: Neuroscience

Neuroscience Antibodies and Assays Market High-End Demand by Rising Industrial With Top Key Players Thermo Fisher, Abcam, Bio-Rad, Merck, Cell…

The Neuroscience Antibodies and Assays Market research Report is a valuable supply of perceptive information for business strategists. This Premium Tyres Market study provides comprehensive data which enhances the understanding, scope and application of this report.

The key market segments along with its subtypes are provided in the report. This report especially focuses on the dynamic view of the market, which can help to manage the outline of the industries. Several analysis tools and standard procedures help to demonstrate the role of different domains in market. The study estimates the factors that are boosting the development of Neuroscience Antibodies and Assays companies.

You can get the sample copy of this report now @https://www.reportsintellect.com/sample-request/220021

Key Companies Covered :Thermo Fisher, Abcam, Bio-Rad, Merck, Cell Signaling Technology, Genscript, Rockland Immunochemicals, BioLegend, Santa Cruz Biotechnology, Roche, Siemens

You get the detailed analysis of the current market scenario for Neuroscience Antibodies and Assays and a market forecast till 2024 with this report. The forecast is also supported with the elements affecting the market dynamics for the forecast period. This report also details the information related to geographic trends, competitive scenarios and opportunities in the Neuroscience Antibodies and Assays market. The report is also equipped with SWOT analysis and value chain for the companies which are profiled in this report.

Most Important Types :Consumables, Instruments

Most Important Application :Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Hospitals & Diagnostic Centers

Get Instant discount @https://www.reportsintellect.com/discount-request/220021

Global Neuroscience Antibodies and Assays Market Size, Status and Forecast 2019 2024

1 Market Overview

2 Manufacturers Profiles

3 Global Neuroscience Antibodies and Assays Sales, Revenue, Market Share and Competition by Manufacturer

4 Global Neuroscience Antibodies and Assays Market Analysis by Regions

5 North America Neuroscience Antibodies and Assays by Countries

6 Europe Neuroscience Antibodies and Assays by Countries

7 Asia-Pacific Neuroscience Antibodies and Assays by Countries

8 South America Neuroscience Antibodies and Assays by Countries

9 Middle East and Africa Neuroscience Antibodies and Assays by Countries

10 Global Neuroscience Antibodies and Assays Market Segment by Type

11 Global Neuroscience Antibodies and Assays Market Segment by Application

12 Neuroscience Antibodies and Assays Market Forecast

13 Sales Channel, Distributors, Traders and Dealers

14 Research Findings and Conclusion

15 Appendixes

Reasons for Buying this Report:

About Us:

Reports Intellect is your one-stop solution for everything related to market research and market intelligence. We understand the importance of market intelligence and its need in todays competitive world.

Our professional team works hard to fetch the most authentic research reports backed with impeccable data figures which guarantee outstanding results every time for you.

So whether it is the latest report from the researchers or a custom requirement, our team is here to help you in the best possible way.

Contact Us:

sales@reportsintellect.com

PH +1-706-996-2486

US Address:

225 Peachtree Street NE,

Suite 400,

Atlanta, GA 30303

Here is the original post:
Neuroscience Antibodies and Assays Market High-End Demand by Rising Industrial With Top Key Players Thermo Fisher, Abcam, Bio-Rad, Merck, Cell...

Our brains map the world in a completely subjective fashion – The Big Smoke Australia

Sigmund Freud long theorised that our reality is influenced by our subconscious. With modern technology, neuroscientists have taken it further.

Modern advances have afforded neuroscientists a more comprehensive look inside the brains of humans as they interact with the world, and how our cranium translates into a cohesive map of the world around us. It has also shown us how subjective and malleable that map is, too.

Sigmund Freud, long before the inception of modern neuroscience, theorised that what we deem objective reality is altered by our subconscious.

Fast forward to now, with the invention of powerful imaging techniques, neuroscientists are now able to peer into the perceptions of people, whether it involves watching events in the environment, thinking about reality or making a decision between several possibilities.

Were able to go a lot deeper into understanding this massive machinery under the hood, says neuroscientist David Eagleman. One particularly interesting facet of our objective reality is the way in which we perceive time. People often report that time seems to slow down during a life-threatening situation, a novel event or even when playing sport.

Eagleman decided to put this to the test. By dropping people from a 150-foot tall tower and measuring their perception of time, he found that people dont necessarily see time moving slowly during an event like this. Rather, the brain creates supremely dense memories of the moment. Upon reflection, when one looks back on a shocking event like this, it appears time moved slower than usual at the moment because of the magnitude of information compressed into such a minuscule amount of time.

Neuroscience has drifted off a little bit from the directions that Freud was going in terms of the interpretations of whether your unconscious mind is sending you particular hidden signals and so on, said Eagleman. But the idea that theres this massive amount happening under the hood, that part was correct and so Freud really nailed that. And he lived before the blossoming of modern neuroscience, so he was able to do this just by outside observation and looking at how people acted.

Dr. Robert Lanza also explores the subjective nature of time in his book, Biocentrism. By penetrating to the bottom of matter, scientists have reduced the universe to its most basic logic, and time is simply not a feature of the external spatial world. Lanza believes that, to understand the fabric that binds the universe, we must take into account the role of the observer. By bringing to light how the electrical activity that occurs within the human brain somehow creates ones reality, Eagleman is carrying us one step closer to a biocentric view of reality.

Eaglemans new television series, The Brain, is almost like a tour of the universe that exists within us all. It wrestles simple yet unanswered questions aimed at helping viewers learn more about what it means to be human: What is reality? and Who is in control?

Nowadays, were able to peer noninvasively inside peoples heads as theyre doing tasks, as theyre thinking about things and making decisions, perceiving the world. Were able to go a lot deeper into understanding this massive machinery under the hood.

The show also provides a greater appreciation for the resiliency and adaptability of the brain. Just as time is altered from observer to observer, our brains dont stop developing. Were not fixed, said Eagleman. From cradle to grave, we are works in progress.

See more here:
Our brains map the world in a completely subjective fashion - The Big Smoke Australia

Thermodynamic Theory of the Brain Aims To Understand Consciousness – Technology Networks

Consciousness is one of the brains most enigmatic mysteries. A new theory, inspired by thermodynamics, takes a high-level perspective of how neural networks in the brain transiently organize to give rise to memories, thought and consciousness.The key to awareness is the ebb and flow of energy: when neurons functionally tag together to support information processing, their activity patterns synchronize like ocean waves. This process is inherently guided by thermodynamic principles, which like an invisible hand promotes neural connections that favors conscious awareness. Disruptions in this process breaks down communication between neural networks, giving rise to neurological disorders such as epilepsy, autism or schizophrenia.

By using thermodynamic principles, such as energy gradients, dissipation and approach to equilibrium, we have a way to start comprehending, or characterizing, how mental things happen and how they sometimes deviate towards neuropathological states, said study author Dr. Jose L. Perez Velazquez affiliated with the Ronin Institute in Montclair, NJ.Energy States as a Guiding PrincipleScientists have long hypothesized that consciousness arises from the coordinated activity among neurons, widely spread across the brain. One framework, the Global Workspace Theory, posits that some brain regions integrate information over space and time across a large number of connected brain areas, resulting in data that is globally available for diverse processes such as memory, attention and language. Another hypothesis, the Integrated Information Theory, believes that consciousness is the result of heavily interconnected brain, the degree of which can be quantified.

Despite decades of work, these theories dont directly tackle the harder question: what are the principles guiding these connections, so that consciousness arises in the brain? As increasing effort focuses on communicating with locked-in patients and determining consciousness in intelligent machines, the pursuit of biological principles guiding brain organization becomes increasingly crucial.

The new work combines classical physics, especially some laws of thermodynamics, with modern recordings of neural activity, to paint a general framework of how changes in free energy the amount of energy available inside a system helps temporarily synchronize the activity in neural networks.

During conscious states, the brain has to actively integrate and segregate information from different senses and so consumes more energy than when unconscious. Using available neural recordings from human participants during wakefulness, sleep, coma and seizures each considered a brain macrostate the team found that entropy during consciousness was higher than that during unconscious states. As a concept, entropy can be interpreted and measured in many specific ways. Here, entropy is associated with the number of configurations of synchronized, or connected, brain networks.

Energy is dissipated as more neurons become connected, say Perez Velazquez and colleagues. Models using thermodynamic equations show that healthy and conscious states have a tendency toward greater dissipation.

However, it is not just about how much free energy is in the brain.

Each macrostate is composed of multiple configurable microstates. During conscious awareness, the brain has an optimal number of connected neural networks, and so many more microstates to support cognition. In contrast, during unconscious states like seizures, there are too many connected neural networks resulting in fewer microstates and so, lower entropy and higher free energy, causing the brain to malfunction.

To maintain healthy brain states then is not about the total amount of energy in the brain [] but rather in how the energy is organized, say the authors.A General Principle of Brain OrganizationTogether, viewing brain organization through the lens energy gradients and dissipation combines into a theory or tentatively, a principle that can separate healthy, conscious brain states from unconscious ones. The team thus believes that their approach can be used to further elucidate what happens when consciousness breaks, for example, in certain epileptic seizures.

Using the principle, the team offered an interpretation about how normal brain activity can transition into abnormal states. When neurons hyperactivate, this results in higher-than-normal synchrony that either lasts too long or reaches too wide regions of the brain. In other words, the brain settles on a state that is too stable. This idea agrees with a previous interpretation of consciousness, detailed in The Brain-Behavior Continuum The subtle transition between sanity and insanity.

As a result, the brain has lower entropy and so reduced ability to form variable brain activity patterns. That is, it has fewer microstates, resulting in fewer configurations of interacting neural networks, which deprives the brain of its usual ability to quickly and flexibly adapt to the outside world. In some cases, consciousness also crumbles.

The team has now laid out experiments to test the theory.ReferencePerez Velazquez et al. (2020) On a Simple General Principle of Brain Organization. Frontiers in Neuroscience. DOI: https://doi.org/10.3389/fnins.2019.01106

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

See original here:
Thermodynamic Theory of the Brain Aims To Understand Consciousness - Technology Networks

Malvern Festival of Ideas announces guest speaker Professor Colin Blakemore – Malvern Gazette

MALVERNS popular festival of ideas is returning once again with a new guest speaker once called 'one of the most powerful scientists in the UK'.

Colin Blakemore, professor of neuroscience and philosophy at the School of Advanced Study at the University of London and emeritus professor of neuroscience at the University of Oxford is the opening speaker at this years festival.

Professor Blakemore is the former chief executive of the British Medical Research Council as well as having hundreds of papers published in research journals.

He has been president of the British Neuroscience Association, the Physiological Society, the British Association for the Advancement of Science (now the British Science Association) and the Society of Biology.

The Observer newspaper once referred to him as One of the most powerful scientists in the UK. In parallel with his academic career, he has also has championed the communication of science and engagement with the public.

He has presented the BBC Reith Lectures and the Royal Institution Christmas Lectures.

In addition, he has written and presented many other programmes about science and written or edited several popular science books. He has also been honorary president of the Association of British Science Writers.

READ MORE: Vets closes due to major water leak

The theme of this years festival, is A Brave New World? and explores what can be done to look positively at the future as well as to what extent can ideas around social policy, economics, medicine, science, politics, psychology, arts, foreign policy and faith lead to a better world.

Speakers include the Labour peer professor baroness Ruth Lister, Dr Irene Guijt, head of research and publishing at Oxfam, Anthony Painter, leader of the research and impact team at the RSA, author and economics commentator Grace Blakeley, and philosopher Dr Julian Baggini. There will be a session on artificial intelligence and its impact on society with Dr Subramanian Ramamoorthy of Edinburgh University and Ivan Bartoletti. The weekend concludes with Peter Tatchell speaking on the future of LGBT+ rights.

All these talks take place at the Chase School and there is a family day at Malvern Cube on Saturday, March 7 with story teller and author Bernadette Russell.

For more information go to malvernfestivalofideas.org.uk/

View original post here:
Malvern Festival of Ideas announces guest speaker Professor Colin Blakemore - Malvern Gazette

BioXcel Therapeutics Announces FDA Clearance of IND Application for BXCL501 for the Treatment of Opioid Withdrawal Symptoms – GlobeNewswire

NEW HAVEN, Conn., Feb. 05, 2020 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (BTI or Company) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to identify and advance the next wave of medicines in neuroscience and immuno-oncology, today announced that its Investigational New Drug (IND) application for BXCL501, the Companys proprietary sublingual thin-film formulation of dexmedetomidine (Dex), has received clearance from the U.S. Food and Drug Administration (FDA) for the treatment of opioid withdrawal symptoms.

The FDA clearance of our IND application for opioid withdrawal, a fourth indication, is an important step in our plans to build a neuroscience franchise around the multiple therapeutic opportunities with BXCL501, commented Vimal Mehta, Chief Executive Officer of BTI. Opioid overdose is reported as the number one cause of death for those under 50 years old in the U.S., and the distressing and challenging symptoms that come with opioid withdrawal are a primary reason for relapse. There is an urgent need for better treatment options to help manage the debilitating withdrawal symptoms and aid this underserved population from continued opioid abuse. BXCL501, our investigational non-opioid therapy, may offer key advantages to treating symptoms due to its intrinsic potency and favorable delivery method. We believe this study will build on the encouraging results we observed in our intravenous (IV) Dex trial, which appeared effective in reducing opioid withdrawal symptoms.

Opioid withdrawal is an emotional and physiological medical condition that may be driven by the excessive drive of noradrenergic neurons that originate from the locus coeruleus in the brainstem. BXCL501 selectively activates alpha-2a adrenergic receptors, which decreases excessive neuronal firing, alleviating the physiological symptoms of opioid withdrawal.

The RELEASE trial is a multicenter, randomized, double-blind, placebo-controlled, ascending-dose Phase 1b/2 study designed to evaluate the safety, pharmacokinetics, tolerability and efficacy of BXCL501 in patients experiencing symptoms of opioid withdrawal. This study will enroll subjects with opioid use disorder who are physically dependent on opioids. Patients will be randomized into multiple dose cohorts of BXCL501, or matching placebo, administered twice daily for five days. The study will assess opioid withdrawal symptoms using both the Clinical Opiate Withdrawal Scale and Short Opiate Withdrawal Scale of Gossop over a 10-day period.

About BXCL501BXCL501 is a potential first-in-class, proprietary sublingual thin film of dexmedetomidine, a selective alpha-2a receptor agonist for the treatment of acute agitation. BTI believes that BXCL501 directly targets a causal agitation mechanism and the Company has observed anti-agitation effects in multiple clinical studies across multiple neuropsychiatric indications. BXCL501 has also been granted Fast Track Designation by the U.S. Food and Drug Administration for the acute treatment of agitation.

A Phase 1b safety and efficacy study of BXCL501 yielded positive dose-response data. BXCL501 is being evaluated in the SERENITY program, consisting of two Phase 3 studies for the acute treatment of agitation in patients with schizophrenia (SERENITY I) and bipolar disorder (SERENITY II). BXCL501 is also being evaluated in a Phase 1b/2 trial for the treatment of agitation associated with dementia, and the Company is preparing to initiate the Phase 1b/2 RELEASE trial of BXCL501 for the treatment of opioid withdrawal symptoms.

About Opioid Drug Withdrawal:

According to the Centers for Disease Control and Prevention (CDC), the misuse of and addiction to opioids is a serious national crisis and is the leading cause of death in the U.S. for those under 50 years old. Between 1999-2017, almost 400,000 people died from an overdose involving an opioid, with greater than 47,000 deaths occurring in 2017 alone. The CDC estimates the total "economic burden" of prescription opioid misuse alone in the U.S. is $78.5 billion a year, including the costs of healthcare, lost productivity, addiction treatment and criminal justice involvement. Opioid withdrawal is a condition characterized by symptoms such as anxiety, agitation, sleep problems, muscle aches, runny nose, sweating, nausea, vomiting, diarrhea and drug craving that occur after stopping or reducing the use of opioids in anyone with physical dependence on opioids.

About BioXcel Therapeutics, Inc.BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company utilizing artificial intelligence to identify improved therapies in neuroscience and immuno-oncology. BTI's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. BTI's two most advanced clinical development programs are BXCL501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neuropsychiatric disorders, and BXCL701, an orally administered systemic innate immunity activator designed for treatment of a rare form of prostate cancer, pancreatic cancer and advanced solid cancers in combination with other immuno-oncology agents. For more information, please visit http://www.bioxceltherapeutics.com/.

Forward-Looking StatementsThis press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include but are not limited to the effects of BXCL501 treatment on opioid withdrawal symptoms and the timing of clinical development initiatives and trials for BXCL501. When used herein, words including anticipate, being, will, plan, may, continue, and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon BTI's current expectations and various assumptions. BTI believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. BTI may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, its limited operating history; its incurrence of significant losses; its need for substantial additional funding and ability to raise capital when needed; its limited experience in drug discovery and drug development; its dependence on the success and commercialization of BXCL501 and BXCL701 and other product candidates; the failure of preliminary data from its clinical studies to predict final study results; failure of its early clinical studies or preclinical studies to predict future clinical studies; its ability to receive regulatory approval for its product candidates; its ability to enroll patients in its clinical trials; its approach to the discovery and development of product candidates based on EvolverAI is novel and unproven; its exposure to patent infringement lawsuits; its ability to comply with the extensive regulations applicable to it; its ability to commercialize its product candidates; and the other important factors discussed under the caption Risk Factors in its Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2019, as such factors may be updated from time to time in its other filings with the SEC, which are accessible on the SECs website at http://www.sec.gov and on the Companys website at http://www.bioxceltherapeutics.com.

These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent managements estimates as of the date of this press release. While BTI may elect to update such forward-looking statements at some point in the future, except as required by law, it disclaims any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing BTIs views as of any date subsequent to the date of this press release.

BioXcel Therapeutics, Inc.www.bioxceltherapeutics.com

Investor Relations:John Grazianojgraziano@troutgroup.com1.646.378.2942

Media:Julia Deutschjdeutsch@troutgroup.com1.646.378.2967

Source: BioXcel Therapeutics, Inc.

View original post here:
BioXcel Therapeutics Announces FDA Clearance of IND Application for BXCL501 for the Treatment of Opioid Withdrawal Symptoms - GlobeNewswire

Researchers reveal new activity above the surface in brain-cell receptors – News-Medical.net

Like buoys bobbing on the ocean, many receptors float on the surface of a cell's membrane with a part sticking above the water and another underwater, inside the cell's cytoplasm. But for cells to function, these receptors must be docked at specific regions of the cell. Most research has focused on the 'underwater' portions. That's where the cell's molecular machines swarm and interact with a receptor's underwater tails, with those interactions then fueling signals that dive deep into the nucleus, changing the cell's course.

New work by a team of Thomas Jefferson University researchers reveals new activity above the surface, in brain-cell receptors that govern learning and chronic pain. In the study, the authors show that the 'above water' portion of proteins can help dock the proteins at synapses, where neurons mediate flow of information throughout the brain. This discovery opens the possibility of using this docking site as a target to develop treatments for chronic pain and other diseases more effectively. The study was published January 29th in Nature Communications.

"The extracellular spaces - the parts 'above the water' - have been largely overlooked," says senior author Matthew Dalva, PhD, professor and vice chair of the Department of Neuroscience and director of the Jefferson Synaptic Biology Center in the Vickie & Jack Institute for Neuroscience - Jefferson Health. Dr. Dalva and his team looked at the NMDAR receptor on brain cells and pinpointed the spot where this receptor interacts with a neighbor to initiate signaling. "When trying to develop new therapy, finding the bullseye is half the problem," says Dr. Dalva.

Finding a key interaction that sits above the cell's surface, could make it more accessible to therapeutics.

The kinds of receptor interactions we're talking about are different than when a receptor binds to its ligand outside of the cell, which is well documented. Here we're describing the kinds of biochemical exchanges - kinase phosphorylation fueled by free-floating ATP - that we thought, until recently, were exclusive to the inside of cells."

Dr. Matthew Dalva, senior author

The researchers focused on the synaptic protein called NMDA-type glutamate receptors (NMDARs), which help regulate the strength of synaptic connections between neurons. It's important that the synapse connects strongly, but not too strongly, in order to prevent creating an overly excitable connection.

A key mechanism controlling synaptic strength is the increase in NMDAR function due to direct molecular interaction with another synaptic protein called the EphB receptor tyrosine kinase. Dr. Dalva and colleagues had previously shown that the phosphorylation of EphB on the "outside" or extracellular portion of the molecule can lead to a direct interaction with NMDARs. And that chemical exchange causes the receptors to cluster and drive neuronal plasticity and chronic pain (PlosBiology 2017). Their new work identifies a specific region of the NMDAR or bullseye, necessary for these proteins to interact.

This specific bullseye could have important medical implications, as disruption of the EphB-NMDAR interaction has been associated with Alzheimer's, and in chronic pain can be due to too much of this interaction. As a trans-synaptic organizer and NMDAR binding protein, the EphB receptor is a key regulator of these events.

However, despite discovery of this interaction over a decade ago, the exact spot where NMDAR interacts with EphB has been a mystery. Here, the researchers demonstrate that specific amino acids in the hinge region of the NDMAR are required to interact with EphB2. Importantly, the amino acids in the hinge region are required for proper NDMAR mobility and stabilization at the synapse.

"There is growing evidence that extracellular interactions may play key regulatory roles in diseases ranging from pain to cancer and even malaria," says Dr. Dalva. "As we begin to define what these exchanges look like, we'll be able to study them, understand their contribution to disease and potentially use them to find better medical interventions."

Source:

Journal reference:

Washburn, H.R., et al. (2020) Positive surface charge of GluN1 N-terminus mediates the direct interaction with EphB2 and NMDAR mobility. Nature Communications. doi.org/10.1038/s41467-020-14345-6.

Follow this link:
Researchers reveal new activity above the surface in brain-cell receptors - News-Medical.net

The Neuroscience Behind What the Crowd Thinks – INSEAD Knowledge

Information about how others feel about pain has an outsized effect on our own response to it.

Pain is central to the human experience. While some suffer in silence, others are wildly vocal about the slightest prick of pain. Understanding pain is necessary to treat and manage it across many acute and chronic medical conditions. At this point in time, science has unveiled some basic physiological mechanisms and the most important networks in the brain where pain is processed. We have developed a better understanding of how pain signals are transmitted from the skin to the brain.

Surprisingly, neuroscience shows us that our experience of pain is not entirely our own the opinions of others can play an outsized role. In other words, peer opinions affect not only our behaviour, but our experience and bodily responses as well. As I explain below, this finding has broad implications for business.

Responses to learned experience and social information

In a recent experiment with Marieke Jepma (University of Amsterdam), Marina Lopez-Sola (Cincinnati Childrens Hospital) and Tor Wager (University of Colorado Boulder), we found that social information about pain increases activity in a particular part of the brain, different from those activated by expectations that we develop based on learning from our own experience.

The aim of this study was to disentangle the components of how we form expectations about pain and how these expectations can influence what we experience. On the one hand, our expectations can be based on our own experiences, for instance, if we recently had a painful medical procedure. On the other hand, expectations are often formed based on what other people tell us about their experiences; social information about how more or less painful events can be. We found that different networks in the brain are involved depending on the source of information.

Each participant in our experiment received 96 short bursts of heat on their leg while in an MRI scanner. The heat was about as hot as a hot coffee cup; painful but bearable for most people. The 36 participants were shown images that indicated either warmer or cooler temperatures (learned experience) and shown an image of a range of opinions about the pain (social information). During the MRI, they rated the one-second touch of heat and we could measure their brains responses.

For learned experiences, participants saw one image that was typically followed by less pain (an animal) and one image that signalled more heat (a vehicle). This allowed us to establish the connection between learned experience and the participants ratings of pain.

Our hypothesis was that the high-pain learning cue, compared to the low-pain cue, would increase the effect of pain, even when followed by a medium temperature. We found this to be true; however, we also found that not all participants learned from the experience.

On the other hand, we found that social information the image showing how others responded to the heat had a significant effect on participants pain responses. This social information effect remained strong, even after 96 trials. Moreover, not only their self-reported experiences, but also their bodily responses, changed to conform with social information. For instance, their palms were sweatier following pain when they were shown the high-pain ratings of others compared to low-pain ratings of others.

Using fMRI, we were also able to see different brain activity patterns in response to the two types of effects. Social information effects were found in the anterior insula, frontal and parietal areas of the brain; specifically its effects on pain were related to activity in the frontoparietal and dorsal attention networks. The learned or conditioned effects were found in limbic areas and in the cerebellum.

Feedback effects

Now that we see how the brain reacts to social information in terms of pain, we can re-examine how the opinions of others impact our own reactions and subsequent choices. Social information is no longer just what our friends and family think. With the proliferation of social media and consumer ratings on internet platforms such as Facebook, Amazon, Yelp and others, social influence happens on a much larger scale. With fake reviews and the possibility of bought ratings on Amazon and other platforms, how do we filter social information?

Given that our research shows that social ratings influence experience, we should also start considering feedback effects. In a recent study with Jepma, we have demonstrated that strong beliefs about pain can prevent learning and lead to a confirmation bias.

As a potential implication for business, if many genuine people have rated a product or a service positively, others experience may be influenced by these ratings. The opposite could be observed for negative ratings. Since ratings influence how the product is perceived, these in turn impact new consumer ratings. One feeding off the other, these effects could create feedback loops, which lead to overly positive or overly negative product ratings.

Self-regulation and the group

Based on the strength of the effects of social information, we need to carefully consider and measure the real-world impact of social ratings and how to potentially regulate them. When ratings are authentic, they can be helpful. Yet, they need to be taken with a grain of salt and a closer look at their authenticity. People need to be better informed about social influence effects, the impact of ratings, and where ratings could come from. Yet, this might be challenging, since most people are unaware of how much they are influenced by others.

In our study, we didnt tell the participants who the other people rating pain were, so the social information was not related to a specific group. Other studies have investigated the role of in-group versus out-group information. In general, people are much more influenced by in-group ratings originating from people who are like them or who are attractive and much less by out-groups. One study with children found that they were more willing to wait for a marshmallow if the rest of their in-group (kids in the same group) also waited. They were less likely to conform if an out-group of other children waited for their treat. Thus, social influence also depends on the source of the information, which may align us even closer to people we already identify with. Together with so-called filter bubbles, this may lead to increased polarisation of in-groups and greater dissent with other groups.

Your own opinion

The large effects of social information have implications for decision making in real life. In our data-driven world, our opinions and behaviours are constantly quantified. Maybe its time to step back from constant evaluation on social media and from checking restaurant ratings before trying one. Our research shows that social information changes not only our overt behaviour, but also strongly colours our judgement. Maybe its time to re-focus our attention to our own actual sensations and prioritise mindful experiences in order to shake the confirmation bias that occurs when we are dazzled by the number of stars next to a product or restaurant.

Leonie Koban is a post-doctoral research fellow in Marketing at INSEAD.

Dont miss our latest content. Download the freeINSEAD Knowledge apptoday.

Follow INSEAD Knowledge onTwitterandFacebook.

Read the rest here:
The Neuroscience Behind What the Crowd Thinks - INSEAD Knowledge

The Neuroscience of Picking a Presidential Candidate – The New Yorker

In the lab, a broad picture window thats actually a one-way mirror looks into the testing room, where subjects are wired up to sensors as they watch videos. The perimeter of the testing room itself is lined with small carrels, each with its own computer workstation. A Webcam is perched atop each monitor. I had already gone through a demonstration of SPARK Neuros system myself, watching a couple of old Super Bowl ads and a grainy clip of the movie Crash, and had seen, precisely, the peaks and valleys of my attention. According to what Ive seen so far, Gerrol said, it seems like you feel empathy and emotion in strong ways, but you do not seem like someone who has massive highs and lows. It was an anodyne analysis that didnt tell me anything I didnt know, but it wasnt supposed to. The more interesting test would happen when the dozen volunteers began to react to the candidates onstage in Des Moines.

To read emotions and gauge attention, a tight plastic cap outfitted with an array of highly conductive metal electrodes was placed over the participants heads as they concentratedor noton a relaxing, intentionally monotonous beach scene playing on the screen in front of them. They could watch waves forming in the middle distance and hear surf lap the shore. Once the electrodes were in place, the electroencephalogram (EEG) cap began to broadcast electrical signalsbrain wavesevery four milliseconds, establishing each participants baseline: essentially, the brain at rest. This would give the researchers a way to measure the intensity of a participants reactions once that tranquil scene was replaced by the rough-and-tumble of the debate. Our brains share a lot in common with how we process information, but were not all coming into it at the same starting point, Gerrol explained. Maybe youre having a good day. Maybe youre having a bad day. Maybe you just had way too much coffee. And so its really important to understand each persons starting point, so the change in the difference from that baseline becomes much more meaningful than some absolute scale.

The researchers also clipped a heart-rate monitor to each persons left earlobe to keep track of vascular changes and attached a galvanic-skin-response (GSR) sensor to their middle and index fingers to measure sweat production, the way a lie detector does. (Sweaty hands typically occur when someone is anxious. Sweat conducts electricity; the greater the signal coming from the GSR, the greater the arousal.) As the participants looked at the computer monitor, the researchers used an eye tracker to see, instantly, exactly where on the screen they were looking, while a Webcam observed tiny, nearly imperceptible changes in their facial expressions. According to Gerrol, EEG makes up the majority of the signal, GSR contributes to converging evidence around emotional arousal, and facial expressions occasionally help.

How SPARK Neuros proprietary algorithm weights all of this data, Gerrol said, is the secret sauce. Its the way that we combine different sensors, from brain activity to peripheral-nervous-system activity, which can provide insights about the nature of emotions, he told me. Sometimes that is clear joy or clear fear or clear anger. However, keep in mind we are measuring emotions, not like versus dislike. Sometimes a politicianwill purposefully evoke fear as part of their strategy, perhaps scaring people, for example, about war and its consequences or about terrorism. Or they will use anger as a strategic rhetorical device, perhaps evoking anger at a lack of action on climate change. In other words, even if we read anger, that does not mean that the person is angry at the candidate; it very well may mean that the candidate did a good job of riling them up on a topic they care about.

Around midnight, when the debate was over, a couple of the volunteers stayed behind to talk with Gerrol and me. We had already seen a graph of the participants reactions; they had not. Michael Bradley Cohen, a thirty-three-year-old actor and licensed New York City tour guide, who is white, had snapped to attention when Bernie Sanders spoke and flatlined when it was Bidens turn. I came here trying to hold my top three candidatesButtigieg, Sanders, and Warren, in that orderin the same place in my head, Cohen told us. But the data appeared to show something else. His strongest reactions were to Warren, Sanders, and then Buttigieg. When Warren, in an advertisement, spoke about a wealth tax, she really got Cohens attention, even though he thought he had been more attuned to a Buttigieg ad that, comparatively, had not elicited much of an emotional response. During the debate, Cohens reaction to Warrens answer to a question about her fitness to serve as Commander-in-Chief showed a sustained set of spikes, each one climbing higher as she continued to talk, like notes moving up a musical staff. When Gerrol pointed this out, Cohen was, as Gerrol predicted, suddenly introspective. I think it was actually really poignant to me, hearing a womans voice on the stage. I know she spoke after Senator Klobuchar, but to hear her speak about this in a way that I trusted felt really good at the time. Yeah, it showed up. Thats what it was. And probably what were also witnessing is that I had a bit of a glow, like, Oh, theres the girl in class that I like, and that might also be what was picked up on.

Faradia Kernizan, who is twenty-nine and black, recently finished a masters degree in public health. She arrived that evening already a Warren supporter, and it showed in the data. When Warren spoke, Kernizans attention moved from her baseline of two all the way up to eight and a half, a jump that Gerrol found especially telling. I mean, thats what I might expect to see if you were watching a horror movie, he said, not something like a debate, with its dry content. But Kernizan didnt find it dry at all. This is our future, she said. I mean, this is all so exciting. Were at a point where, I mean, hopefully, things will change and maybe we get a different leader, and I think were at a point where we can get somebody that we really believe in.

She was paying special attention to Warrens views on foreign policy, she said, so she would be able to repeat them to friends and family members she hoped to convince to vote for Warren. But Kernizan was also attuned to some of the other candidates as well, like Biden, since there was a chance that he would be the nominee, and Sanders, whom she supported in 2016. That Cohen and Kernizan were not especially moved by the political ads didnt surprise Gerrol. My impression, having studied thousands and thousands of ads, is that political ads are especially boring. The Bloomberg ad, Cohen said, looked like he was running for President in 1988. As Cohen watched it, his attention dropped to his baseline.

A few days after we had gone through this exercise, I got an e-mail from Gerrol telling me about a third participant, whose attention graph looked similar to Cohens and Kernizans, with significant surges of attention when Sanders and Warren were speaking. The difference was that, unlike Cohen and Kernizan, that participants attention was an expression of his antipathy: Sanders and Warren were his least favorite candidates. It was a perfect illustration of the danger of conflating attention with affection. We had seen something similar, too, when Cohens graph showed his attention picking up every time one of the candidates mentioned Trump. Yeah, when we hear the name Voldemort, Cohen said, we all have a response.

Go here to see the original:
The Neuroscience of Picking a Presidential Candidate - The New Yorker

Study Links Autism To ‘Insulation’ That Coats Brain Cells And Speeds Signals : Shots – Health News – NPR

This image from an electron microscope shows a cross-sectional view of an oligodendrocyte (blue) among nerve fibers coated with myelin (dark red). In models of autism spectrum disorder, oligodendrocytes appear to create too much or too little myelin. Jose Luis Calvo/Science Source hide caption

This image from an electron microscope shows a cross-sectional view of an oligodendrocyte (blue) among nerve fibers coated with myelin (dark red). In models of autism spectrum disorder, oligodendrocytes appear to create too much or too little myelin.

Scientists have found a clue to how autism spectrum disorder disrupts the brain's information highways.

The problem involves cells that help keep the traffic of signals moving smoothly through brain circuits, a team reported Monday in the journal Nature Neuroscience.

The team found that in both mouse and human brains affected by autism, there's an abnormality in cells that produce a substance called myelin.

That's a problem because myelin provides the "insulation" for brain circuits, allowing them to quickly and reliably carry electrical signals from one area to another. And having either too little or too much of this myelin coating can result in a wide range of neurological problems.

For example, multiple sclerosis occurs when the myelin around nerve fibers is damaged. The results, which vary from person to person, can affect not only the signals that control muscles, but also the ones involved in learning and thinking.

The finding could help explain why autism spectrum disorders include such a wide range of social and behavioral features, says Brady Maher, a lead investigator at the Lieber Institute for Brain Development and an associate professor in the psychiatry department at Johns Hopkins School of Medicine.

"Myelination could be a problem that ties all of these autism spectrum disorders together," Maher says. And if that's true, he says, it might be possible to prevent or even reverse the symptoms using drugs that affect myelination.

"If we get to these kids really early, we might be able to change their developmental trajectory and improve their outcomes," Maher says.

"It's possible to make these cells healthier," adds Dr. Daniel Weinberger, director of the Lieber Institute and a professor at Johns Hopkins. "And it's never been a target of treatment in autism."

The study adds to the evidence that myelination problems are present in "several developmental disorders and in particular in autism," says Dr. Flora Vaccarino, a professor in the neuroscience department at Yale who was not involved in the research.

It also shows how one faulty regulatory system in the brain can lead to either too much myelination or too little, she says. And that may help explain why people with autism spectrum disorders may have brains that are either unusually large or unusually small.

Researchers involved in the study came upon the myelination problem while looking for something else.

They were studying brain cells in mice with a gene mutation that causes Pitt-Hopkins syndrome, which can include features of autism spectrum disorder. "We saw a signature that suggested there might be something wrong with myelination," Maher says. "So that was pretty surprising to us."

More experiments confirmed that "there was a clear deficit," in the cells that control myelination, which are called oligodendrocytes, he says. This was true not only in mice with the Pitt-Hopkins syndrome, but in other mouse models of autism, too.

Next, a biostatistics expert named Andrew Jaffe looked at a genetic analysis of brain tissue from people with autism who had died. And that experiment also found problems with the system that controls myelination.

To fully understand what's going on though, the problem needs to be studied in developing brain tissue, Vaccarino says.

That should be possible, she says, using tiny clusters of human brain cells called brain organoids, which can be grown in a petri dish. Vaccarino's lab has created brain organoids from the cells of people with autism spectrum disorder, which might reveal how the myelination problems begin, she says.

Brain myelination "really does not start in earnest until the first year or two of life," Weinberger says. "And this is around the time that autism is first apparent."

That might eventually mean a treatment that corrected a problem with myelination could help children who are diagnosed early in life, he says. Several such treatments are being developed to treat people with multiple sclerosis, a disease that erodes myelin.

Go here to see the original:
Study Links Autism To 'Insulation' That Coats Brain Cells And Speeds Signals : Shots - Health News - NPR

Q&A: Student conducts research on stress in adolescents – The Ithacan

For many students in the Ithaca College School of Health Sciences and Human Performance, conducting their own research is the ultimate goal. Senior Justina Snyder is already well on her way to achieving it.

Snyder is a clinical health studies major, which is part of the sixyear physical therapy program, and she has minors in neuroscience, psychology and honors. Snyder was inspired to start her own research project in the fall of her sophomore year after taking a behavioral neuroscience course taught by Tamara Fitzwater, assistant professor in the Department of Psychology.

With Fitzwaters guidance, the two worked together to study how physical stress impacts the brains and behaviors of adolescents. Last spring, Snyder and Fitzwater applied for the Academic Challenge Grant from the Office of the Provost, which provides funding to student-faculty teams involved in collaborative research projects. Synder said she plans to use her findings in her honors thesis, a final project that is required for seniors completing the honors minor in interdisciplinary studies.

Staff writer Ryan Bieber sat down with Snyder to discuss the inspiration for her research and the process of writing her thesis.

This interview has been edited for length and clarity.

Ryan Bieber: What made you want to major in physical therapy?

Justina Snyder: I always kind of knew I wanted to be in the medical or health care field, and, when I was looking at different options, I realized PTs actually get to sit down with their patients and develop a rapport. I really like building connections with people, and I thought that was a better way for me to be able to help people meet their goals and get better.

RB: How did you come up with the idea for your honors thesis?

JS: I knew stress was always a really big topic of discussion, and I kind of wanted to tie it into PT. I was kind of thinking about how stress impacts peoples ability to perform tasks and tying that into PT and neuroscience in general to see how stress affects the brain.

RB: How has the honors program played a role in your research?

JS: The whole purpose of the Honors Program is interdisciplinary, so they want you to take classes outside of your given major and explore different themes and topics. I really like this project because its taking my psych and neuroscience background and pairing it with PT and the classes Ive taken within the Honors Program and kind of putting it all together. Its cool to see things from different perspectives both in the neuroscience and psychology realms.

RB: What was your reaction when you found out you received the grant?

JS: We were really happy that we were able to secure the money to do the project. It was kind of nerve-racking because if we didnt get this money, I dont know that our project would have been able to happen. Science research in general is just really expensive, so we knew this was a great way we could get funding for the project.

RB: What phase are you at in your research?

JS: We did all the hands-on work last semester. This semester is really geared toward me writing my thesis. Were exploring the opportunity to present at the Whalen Symposium here on campus, which is kind of a bucket list thing for me.

RB: Whats the most important takeaway from your research?

JS: Research projects are a fluid process, so you have to adjust. Theres going to be challenges and deadlines or something might not go as planned, and you just have to make adjustments to it. Its been a great learning process.

RB: How do you balance all the classes in your major and minors with your research?

JS: It just comes down to organization and having a passion for things. Its about all of the knowledge Ive gained, the experiences Ive had and the people Ive met. Its about having the drive and the passion to do it.

Read more:
Q&A: Student conducts research on stress in adolescents - The Ithacan